​

Viridian Therapeutics (VRDN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRDN Stock Forecast

Viridian Therapeutics (VRDN) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $22.75, with a high of $28.00 and a low of $19.00. This represents a 17.09% increase from the last price of $19.43.

$10 $14 $18 $22 $26 $30 High: $28 Avg: $22.75 Low: $19 Last Closed Price: $19.43

VRDN Stock Rating

Viridian Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (90.91%), 1 Hold (9.09%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 10 Strong Sell Sell Hold Buy Strong Buy

VRDN Forecast vs Benchmarks

TypeNameUpside
StockViridian Therapeutics17.09%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-114
Avg Price Target-$20.50$19.43
Last Closing Price$19.43$19.43$19.43
Upside/Downside-5.51%-
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 255102--17
Dec, 245112--18
Nov, 247111--19
Oct, 247102--19
Sep, 247102--19
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 12, 2024Alex ThompsonStifel Nicolaus$20.50$11.4179.67%5.51%
Sep 13, 2024Gregory RenzaRBC Capital$22.00$10.35112.56%13.23%
Sep 11, 2024Serge BelangerNeedham$19.00$9.5199.79%-2.21%
Sep 11, 2024Kalpit PatelB.Riley Financial$22.00$19.2414.35%13.23%
Sep 10, 2024Alex ThompsonStifel Nicolaus$20.00$8.68130.41%2.93%
Sep 10, 2024Julian HarrisonBTIG$28.00$8.64224.07%44.11%
Aug 14, 2024Richard LawGoldman Sachs$25.00$14.1876.30%28.67%
Jun 11, 2024Gregory RenzaRBC Capital$17.50$6.48170.06%-9.93%
Jun 11, 2024Julian HarrisonBTIG$23.00$6.48254.94%18.37%
Jun 10, 2024Andy ChenWolfe Research$14.50$6.11137.32%-25.37%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2025WedbushOutperformOutperformhold
Oct 28, 2024NeedhamBuyBuyhold
Sep 13, 2024RBC CapitalOutperformOutperformhold
Sep 11, 2024NeedhamBuyBuyhold
Sep 11, 2024H.C. WainwrightBuyBuyhold
Sep 10, 2024WedbushBuyBuyhold
Sep 10, 2024BTIGBuyBuyhold
Aug 15, 2024WedbushBuyBuyhold
Aug 14, 2024Goldman SachsBuyBuyhold
Jul 16, 2024OppenheimerBuyBuyhold

Financial Forecast

EPS Forecast

$-35 $-27 $-19 $-11 $-3 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-31.20$-6.66$-3.91$-0.01-----
Avg Forecast$-5.11$-5.38$-3.56$-4.94$-4.03$-4.16$-4.21$-1.53$1.37
High Forecast$-13.48$-14.20$-9.63$-5.48$-4.17$-4.67$-6.61$-4.08$0.56
Low Forecast$-1.09$-1.14$-1.61$-4.63$-3.85$-3.61$-2.35$3.81$2.84
Surprise %510.57%23.79%9.83%-99.80%-----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.05M$2.96M$1.77M$314.00K-----
Avg Forecast$866.67K$3.00M$2.13M$373.08K$317.29K$239.29K$45.91M$333.37M$667.21M
High Forecast$341.67K$1.18M$1.23M$240.70K$235.03K$130.52K$43.63M$333.37M$363.93M
Low Forecast$1.96M$6.78M$4.92M$830.41K$411.30K$435.06K$48.18M$333.37M$1.21B
Surprise %21.15%-1.30%-16.72%-15.84%-----

Net Income Forecast

$-650M $-480M $-310M $-140M $30M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-110.98M$-79.42M$-125.44M$-237.73M-----
Avg Forecast$-228.78M$-240.98M$-159.21M$-237.73M$-179.56M$-185.24M$-200.63M$-134.61M$61.50M
High Forecast$-603.39M$-635.58M$-431.02M$-245.13M$-186.72M$-208.80M$-295.96M$-182.64M$25.16M
Low Forecast$-48.61M$-51.21M$-71.93M$-207.35M$-172.40M$-161.68M$-105.31M$170.56M$126.91M
Surprise %-51.49%-67.04%-21.21%------

VRDN Forecast FAQ

Is Viridian Therapeutics stock a buy?

Viridian Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Viridian Therapeutics is a favorable investment for most analysts.

What is Viridian Therapeutics's price target?

Viridian Therapeutics's price target, set by 11 Wall Street analysts, averages $22.75 over the next 12 months. The price target range spans from $19 at the low end to $28 at the high end, suggesting a potential 17.09% change from the previous close price of $19.43.

How does Viridian Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Viridian Therapeutics stock forecast shows a 17.09% upside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Viridian Therapeutics over the past three months?

  • January 2025: 29.41% Strong Buy, 58.82% Buy, 11.76% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 27.78% Strong Buy, 61.11% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 36.84% Strong Buy, 57.89% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.

What is Viridian Therapeutics’s EPS forecast?

Viridian Therapeutics's average annual EPS forecast for its fiscal year ending in December is -4.03 for 2024, a 40200.00% increase from the reported $-0.01 in 2023. The prediction for 2025 is $-4.16, $-4.21 for 2026, $-1.53 for 2027, and $1.37 for 2028.

What is Viridian Therapeutics’s revenue forecast?

Viridian Therapeutics's average annual revenue forecast for its fiscal year ending in December is $317.29K for 2024, a 1.05% increase from the reported $314K in 2023. The forecast for 2025 is $239.29K, $45.91M for 2026, $333.37M for 2027, and $667.21M for 2028.

What is Viridian Therapeutics’s net income forecast?

For its fiscal year ending in December, Viridian Therapeutics's average annual net income forecast is $-180M for 2024, reflecting a -24.47% decrease from the reported $-238M in 2023. The projection for 2025 is $-185M, $-201M for 2026, $-135M for 2027, and $61.5M for 2028.